Tag

Biotech Startups

All articles tagged with #biotech startups

Fierce Biotech Unveils 2026 Fierce 15: A Focus on Fertility, Oncology, and AI
biotechnology15 days ago

Fierce Biotech Unveils 2026 Fierce 15: A Focus on Fertility, Oncology, and AI

Fierce Biotech has released its 2026 Fierce 15 list, highlighting 15 private biotech companies selected for their innovative approaches to unmet medical needs. The list includes Alveus Therapeutics, Beacon Therapeutics, EpiBiologics, Expedition Medicines, Freya Biosciences, Infinimmune, Neomorph, Nuclidium, Pelage Pharmaceuticals, ReproNovo, and SonoThera. These companies span therapeutic areas including obesity, eye disease, oncology, immunology, reproductive health, and radiopharmaceuticals. The selection reflects a broader industry trend of capital returning to early-stage biotech, with several companies securing significant funding rounds and partnerships with major pharmaceutical firms.

Endpoints News Unveils 2026 Top 11 Biotech Startups Amid Industry Shifts
biotechnology25 days ago

Endpoints News Unveils 2026 Top 11 Biotech Startups Amid Industry Shifts

Endpoints News has released its 2026 Endpoints 11 list, highlighting 11 private biotech startups selected from over 150 nominations. The awards, announced at a Boston gala, recognize companies making significant bets in gene therapy, oncology, and AI, reflecting a biotech sector that is recovering financially but facing new structural uncertainties.

NewLimit raises $435M to launch its first liver-focused clinical trial
business4 months ago

NewLimit raises $435M to launch its first liver-focused clinical trial

NewLimit, a South San Francisco longevity biotech, secured $435 million in a Series C led by Founders Fund (with Thrive Capital, Lilly Ventures, Nat Friedman, and Daniel Gross) valuing the company at about $3.1 billion as it moves toward its first liver-focused clinical trial. Founders include Brian Armstrong, Blake Byers, and Jacob Kimmel, with prior rounds of $130 million in May 2025 and $45 million in October 2025.

Radiopharmaceutical Growth Stalled by Talent Shortage
biotechnology1 year ago

Radiopharmaceutical Growth Stalled by Talent Shortage

The rise of radiopharmaceuticals, a new cancer treatment that targets cancer cells with radioactive isotopes, is facing a significant talent shortage. This innovative approach has attracted numerous biotech startups and substantial investments, with several companies being acquired for over $1 billion. However, the industry's growth is threatened by a lack of skilled professionals needed to develop and implement these therapies.